185 related articles for article (PubMed ID: 32401624)
1. Concerns about the safety of anti-TNF agents when treating rheumatic diseases.
Atzeni F; Nucera V; Gerratana E; Cirillo M; Marino F; Miceli G; Sangari D; Boccassini L; Masala IF
Expert Opin Drug Saf; 2020 Jun; 19(6):695-705. PubMed ID: 32401624
[TBL] [Abstract][Full Text] [Related]
2. Toxicological considerations in the treatment of axial spondylo-arthritis.
Marino F; D'Angelo S; Masala IF; Gerratana E; Nucera V; La Corte L; Giallanza M; Sarzi-Puttini P; Atzeni F
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):663-672. PubMed ID: 32552128
[TBL] [Abstract][Full Text] [Related]
3. Risks associated with use of TNF inhibitors in children with rheumatic diseases.
Marino A; Giani T; Cimaz R
Expert Rev Clin Immunol; 2019 Feb; 15(2):189-198. PubMed ID: 30451548
[No Abstract] [Full Text] [Related]
4. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents.
Atzeni F; Talotta R; Masala IF; Gerardi MC; Casale R; Sarzi-Puttini P
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):500-510. PubMed ID: 31174819
[TBL] [Abstract][Full Text] [Related]
6. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?
Wroński J; Fiedor P
J Clin Pharmacol; 2019 Apr; 59(4):445-462. PubMed ID: 30476367
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.
Criscione LG; St Clair EW
Curr Opin Rheumatol; 2002 May; 14(3):204-11. PubMed ID: 11981314
[TBL] [Abstract][Full Text] [Related]
8. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.
Matucci A; Cammelli D; Cantini F; Goletti D; Marino V; Milano GM; Scarpa R; Tocci G; Maggi E; Vultaggio A
Expert Opin Drug Saf; 2016 Dec; 15(sup1):3-10. PubMed ID: 27924646
[TBL] [Abstract][Full Text] [Related]
9. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
10. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
11. Problems encountered during anti-tumour necrosis factor therapy.
Desai SB; Furst DE
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
13. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor as a therapeutic target of rheumatologic disease.
Ackermann C; Kavanaugh A
Expert Opin Ther Targets; 2007 Nov; 11(11):1369-84. PubMed ID: 18028004
[TBL] [Abstract][Full Text] [Related]
16. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
Hochberg MC; Lebwohl MG; Plevy SE; Hobbs KF; Yocum DE
Semin Arthritis Rheum; 2005 Jun; 34(6):819-36. PubMed ID: 15942917
[TBL] [Abstract][Full Text] [Related]
17. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
18. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
19. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.
Jain A; Singh JA
Immunotherapy; 2013 Mar; 5(3):265-99. PubMed ID: 23444956
[TBL] [Abstract][Full Text] [Related]
20. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
